

Oncology Today with Dr Neil Love: Newly Approved Agents in the Management of Urothelial Bladder Carcinoma (Presentation Video)**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Of the toxicities listed below, which are more commonly experienced by patients who are receiving enfortumab vedotin?**
 - Hypertension and myocardial ischemia
 - Thrombocytopenia, pneumonitis and diarrhea
 - Rash, ocular toxicities and peripheral neuropathy**
- 2. Erdafitinib is FDA approved for which patients with locally advanced or metastatic urothelial bladder carcinoma (UBC)?**
 - All patients with disease refractory to or in relapse after platinum-containing chemotherapy
 - Patients whose tumors have high levels of PD-L1 expression
 - Patients with FGFR2 or FGFR3 genetic alterations and disease refractory to or in relapse after platinum-containing chemotherapy**
- 3. Recommendations for mitigating the hyperphosphatemia associated with erdafitinib include which of the following options?**
 - Withhold drug
 - Reduce dose
 - Add an oral phosphate binder
 - All of the above**
 - Both a and c
- 4. Which drug type best describes the mechanism of action of sacituzumab govitecan?**
 - Anti-PD-1 monoclonal antibody
 - Anti-PD-L1 monoclonal antibody
 - Antibody-drug conjugate targeting Trop-2**